Pyxis Oncology rakes in $22 mln Series A
Boston-based Pyxis Oncology, a newly formed immuno-oncology company, has raised $22 million in Series A funding. Leaps by Bayer led the round with participation from other investors that included Agent Capital, Ipsen and Longwood Fund.
17 July 2019•1 min read
